Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran

Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran

Atrial fibrillation (AF) is the most frequent type of supraventricular arrhythmias. The anticoagulant therapy should be prescribed to prevent thromboembolic events. According to randomized clinical trials, anticoagulants do not always prove their high efficiency in the real clinical practice. It is...

Full description

Bibliographic Details
Main Authors:	N. A. Novikova, Z. K. Salpagarova, M. I. Chashkina, A. A. Bykova, Z. A. Alimova, А. S. Yadykina, D. F. Mesitskaya, N. A. Babakova, D. A. Andreev
Format:	Article
Language:	English
Published:	Столичная издательская компания 2021-05-01
Series:	Рациональная фармакотерапия в кардиологии
Subjects:	atrial fibrillation chronic kidney disease anticoagulants warfarin bleeding
Online Access:	https://www.rpcardio.online/jour/article/view/2426

Similar Items

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
by: Xiaoxi Yao, et al.
Published: (2016-06-01)

Specifics of anticoagulation in combination with atrial fibrillation and chronic kidney disease
by: N. Sh. Zagidullin, et al.
Published: (2021-10-01)

Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation
by: Brandon K. Martinez, et al.
Published: (2018-04-01)

Warfarin vs. apixaban in nonvalvular atrial fibrillation, and analysis by concomitant antiarrhythmic medication use: A national retrospective study
by: Matthew A. Wanat, et al.
Published: (2019-10-01)

Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation
by: N. A. Novikova, et al.
Published: (2016-11-01)

Association of anticoagulant-related bleeding events with cancer detection in atrial fibrillation: A systematic review and meta-analysis
by: Anastasios Papanastasiou, et al.
Published: (2021-09-01)

ANTICOAGULANT THERAPY FOR CHRONIC KIDNEY DISEASE AND ATRIAL FIBRILLATION: THE AXIS OF ROTATION BETWEEN THE POLES OF RISK
by: Z. D. Kobalava, et al.
Published: (2018-06-01)

Anticoagulant therapy control in primary healthcare setting
by: Z. K. Salpagarova, et al.
Published: (2022-12-01)

Assessment of Antithrombotic Therapy in Patients with Atrial Fibrillation for 2015-2017 According to the Registry of the Clinic of the Scientific Research Institute of Medical Problems of the North of Krasnoyarsk City
by: A. A. Tuchkov, et al.
Published: (2019-03-01)

ANTICOAGULATION CONTROL AMONG PATIENTS WITH ATRIAL FIBRILLATION
by: Amer Rauf, et al.
Published: (2020-12-01)

Anticoagulant therapy in catheter ablation of atrial fibrillation and flutter
by: M. V. Serova, et al.
Published: (2021-09-01)

ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS
by: M. Yu. Gilyarov, et al.
Published: (2016-01-01)

Direct Oral Anticoagulant Adherence of Patients With Atrial Fibrillation Transitioned from Warfarin
by: Krishna N. Pundi, et al.
Published: (2021-12-01)

Resumption of anticoagulant therapy after major bleeding and recurrence of hemorrhagic complications in patients with atrial fibrillation with a high risk of stroke and thromboembolism (based on the results of 20 years of observation)
by: A. I. Mironova (Staroverova), et al.
Published: (2020-10-01)

Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease
by: V. I. Petrov, et al.
Published: (2019-09-01)

Algorithm for the Choice of Anticoagulant for Patients with Atrial Fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2020-05-01)

Optimal INR level in patients with atrial fibrillation with EHRA type 2 valvular heart disease receiving warfarin
by: Sirote Luengsupabul, et al.
Published: (2020-06-01)

Dabigatran in the prevention of stroke in nonvalvular atrial fibrillation: Complex clinical situations and real clinical practice
by: O N Tkacheva, et al.
Published: (2014-04-01)

Factors driving the use of warfarin and non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
by: Mu-Mei Hu, et al.
Published: (2017-04-01)

Long-term comparative effectiveness and safety of dabigatran, rivaroxaban, apixaban and edoxaban in patients with atrial fibrillation: A nationwide cohort study
by: Maxim Grymonprez, et al.
Published: (2023-02-01)

Warfarin and the Risk of Death, Stroke, and Major Bleeding in Patients With Atrial Fibrillation Receiving Hemodialysis: A Systematic Review and Meta-Analysis
by: Hong Lei, et al.
Published: (2018-11-01)

Warfarin therapy in atrial fibrillation: assessment of patient knowledge of risks and benefits
by: P. Fitzgerald, et al.
Published: (2020-05-01)

Contribution of anticoagulant therapy adherence to the risk of complications of atrial fibrillation
by: Yu. P. Skirdenko, et al.
Published: (2019-03-01)

Anticoagulation for Atrial Fibrillation in End-stage Kidney Disease
by: Gavin Lee, et al.
Published: (2015-10-01)

Traditional warfarin (Coumadin) therapy usage experience on nonvalvular atrial fibrillation before non-Vitamin K antagonists (new oral anticoagulants) era from a center in Turkey
by: Emre Ozdemir, et al.
Published: (2020-01-01)

Dabigatran Compared with Warfarin for Stroke Prevention in Patients with Atrial Fibrillation: An Evidence Based Case Report
by: Alvin Nursalim, et al.
Published: (2013-06-01)

Warfarin doses for anticoagulation therapy in elderly patients with chronic atrial fibrillation
by: Antonio de Padua Mansur, et al.
Published: (2012-01-01)

Characteristics and 2‐year outcomes of dabigatran treatment in patients with heart failure and atrial fibrillation: GLORIA‐AF
by: Sergio J. Dubner, et al.
Published: (2020-10-01)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
by: Chung-Ming Fu, et al.
Published: (2021-10-01)

Severe gastrointestinal bleeding in patients with atrial fibrillation receiving oral anticoagulants (based on REGistry of long-term AnTithrombotic TherApy – REGATTA)
by: Ekaterina S. Kropacheva, et al.
Published: (2021-09-01)

Postoperative Atrial Fibrillation: A Review
by: Sidra Shah, et al.
Published: (2024-09-01)

Risk of Ischemic Bowel Disease in Patients With Atrial Fibrillation Receiving Warfarin or Non-vitamin K Antagonist Oral Anticoagulants
by: Jo-Nan Liao, et al.
Published: (2022-07-01)

Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice
by: A. A. Zarudsky, et al.
Published: (2020-03-01)

Meta‐analysis evaluating apixaban in patients with atrial fibrillation and end‐stage renal disease requiring dialysis
by: Ahmed AlTurki, et al.
Published: (2024-06-01)

Does Warfarin or Rivaroxaban at Low Anticoagulation Intensity Provide a Survival Benefit to Asian Patients With Atrial Fibrillation?
by: Dong Lin, et al.
Published: (2021-11-01)

Efficacy and Safety of Edoxaban in Patients With Active Malignancy and Atrial Fibrillation: Analysis of the ENGAGE AF‐TIMI 48 Trial
by: Christina L. Fanola, et al.
Published: (2018-08-01)

Newer Anticoagulants for Non-Valvular Atrial Fibrillation
by: Joseph M. Harburger, et al.
Published: (2012-05-01)

Nonvitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients and Risk of Dementia: A Nationwide Propensity‐Weighted Cohort Study
by: Mette Søgaard, et al.
Published: (2019-06-01)

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation
by: Josef Finsterer, et al.
Published: (2012-02-01)

Comparison of benefit between dabigatran and warfarin among patients with atrial fibrillation: A systematic review
by: Amal K Sulieman
Published: (2016-01-01)